Multiple Myeloma Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US

DelveInsight's "Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Multiple Myeloma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple Myeloma Market Forecast
https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Multiple Myeloma Market Report:
• The Multiple Myeloma market size was valued approximately USD 20 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In October 2022, Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, revealed that the US FDA had granted accelerated approval to TECVAYLI (teclistamab) for adult patients dealing with relapsed or refractory multiple myeloma. These patients must have undergone a minimum of four prior lines of therapy, which includes treatment with a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
• The FasTCAR-T therapy named GC012F, which dual-targets BCMA and CD19, shows encouraging rates of minimal residual disease (MRD) negativity and stringent complete response in patients with High-Risk Relapsed/Refractory Multiple Myeloma.
• Positive extended-term results from the TRiMM-2 trial demonstrate an overall response rate exceeding 80% when utilizing the Talquetamab and DARZALEX FASPRO combination on a biweekly regimen for Relapsed/Refractory Multiple Myeloma.
• In 2022, as per the Surveillance, Epidemiology, and End Results (SEER), it is anticipated that approximately 34,470 new cases of multiple myeloma will be reported in the United States.
• In 2020, the overall number of reported cases of multiple myeloma in the 7MM (Seven Major Markets) was 70,577, with the United States contributing the highest count at 32,270 cases. This figure, which was the highest among the seven major markets, is anticipated to potentially rise in the forecast period.
• In 2020, Germany, within the EU4 and the UK, recorded the highest incidence of multiple myeloma cases, with a total of 7,600 reported cases.
• Key Multiple Myeloma Companies: AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US Oncology Research, Cartesian Therapeutics, GlaxoSmithKline, Targovax ASA, Janssen Research & Development, AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others
• Key Multiple Myeloma Therapies: Venetoclax, ABBV 383, Talquetamab, Linvoseltamab, Descartes 08, Lenalidomide, Selinexor, Descartes-25, Pomalidomide, TG01, Cyclophosphamide, AZD0305, bb2121, EOS884448, Elranatamab, APG-2575, TNB-383B, PHE885, and others
• The Multiple Myeloma epidemiology based on gender analyzed that males are affected more in case of Multiple Myeloma as compared to females.
• The Multiple Myeloma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple Myeloma pipeline products will significantly revolutionize the Multiple Myeloma market dynamics.

Multiple Myeloma Overview
Multiple myeloma is a type of cancer that forms in plasma cells, which are a type of white blood cell. Plasma cells are responsible for producing antibodies that help the body fight off infections. In multiple myeloma, malignant plasma cells accumulate in the bone marrow, crowding out healthy blood cells and leading to various complications.

Get a Free sample for the Multiple Myeloma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Multiple Myeloma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Multiple Myeloma Epidemiology Segmentation:
The Multiple Myeloma market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Multiple Myeloma
• Prevalent Cases of Multiple Myeloma by severity
• Gender-specific Prevalence of Multiple Myeloma
• Diagnosed Cases of Episodic and Chronic Multiple Myeloma

Download the report to understand which factors are driving Multiple Myeloma epidemiology trends @ Multiple Myeloma Epidemiology Forecast
https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Multiple Myeloma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Myeloma market or expected to get launched during the study period. The analysis covers Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Multiple Myeloma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Multiple Myeloma Therapies and Key Companies
• Venetoclax: AbbVie and Roche
• ABBV 383: AbbVie
• Talquetamab: Janssen Pharmaceutical
• Linvoseltamab: Regeneron Pharmaceuticals
• Descartes 08: Cartesian Therapeutics
• Lenalidomide: Alliance Foundation Trials, LLC.
• Selinexor: US Oncology Research
• Descartes-25: Cartesian Therapeutics
• Pomalidomide: GlaxoSmithKline
• TG01: Targovax ASA
• Cyclophosphamide: Janssen Research & Development
• AZD0305: AstraZeneca
• bb2121: Celgene
• EOS884448: Bristol-Myers Squibb
• Elranatamab: Pfizer
• APG-2575: Ascentage Pharma Group Inc.
• TNB-383B: TeneoOne Inc.
• PHE885: Novartis

Discover more about therapies set to grab major Multiple Myeloma market share @ Multiple Myeloma Treatment Landscape
https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Multiple Myeloma Market Strengths
• Emerging therapies such as CAR-T cell and monoclonal antibodies showing promising results in treating multiple myeloma patients and expected to drive the growth of market. It also amends the treatment landscape in cancer due to its high specificity and minimal side effect profile.

Multiple Myeloma Market Opportunities
• BCMA-targeting therapies are expected to result in noteworthy revenues due to premium pricing and clinical benefit in heavily pretreated patients.

Scope of the Multiple Myeloma Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Multiple Myeloma Companies: AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US Oncology Research, Cartesian Therapeutics, GlaxoSmithKline, Targovax ASA, Janssen Research & Development, AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others
• Key Multiple Myeloma Therapies: Venetoclax, ABBV 383, Talquetamab, Linvoseltamab, Descartes 08, Lenalidomide, Selinexor, Descartes-25, Pomalidomide, TG01, Cyclophosphamide, AZD0305, bb2121, EOS884448, Elranatamab, APG-2575, TNB-383B, PHE885, and others
• Multiple Myeloma Therapeutic Assessment: Multiple Myeloma current marketed and Multiple Myeloma emerging therapies
• Multiple Myeloma Market Dynamics: Multiple Myeloma market drivers and Multiple Myeloma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Multiple Myeloma Unmet Needs, KOL's views, Analyst's views, Multiple Myeloma Market Access and Reimbursement

To know more about Multiple Myeloma companies working in the treatment market, visit @ Multiple Myeloma Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Multiple Myeloma Market Report Introduction
2. Executive Summary for Multiple Myeloma
3. SWOT analysis of Multiple Myeloma
4. Multiple Myeloma Patient Share (%) Overview at a Glance
5. Multiple Myeloma Market Overview at a Glance
6. Multiple Myeloma Disease Background and Overview
7. Multiple Myeloma Epidemiology and Patient Population
8. Country-Specific Patient Population of Multiple Myeloma
9. Multiple Myeloma Current Treatment and Medical Practices
10. Multiple Myeloma Unmet Needs
11. Multiple Myeloma Emerging Therapies
12. Multiple Myeloma Market Outlook
13. Country-Wise Multiple Myeloma Market Analysis (2019-2032)
14. Multiple Myeloma Market Access and Reimbursement of Therapies
15. Multiple Myeloma Market Drivers
16. Multiple Myeloma Market Barriers
17. Multiple Myeloma Appendix
18. Multiple Myeloma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Multiple Myeloma Pipeline https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Multiple Myeloma Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Multiple Myeloma market. A detailed picture of the Multiple Myeloma pipeline landscape is provided, which includes the disease overview and Multiple Myeloma treatment guidelines.
Multiple Myeloma Epidemiology https://www.delveinsight.com/report-store/multiple-myeloma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Multiple Myeloma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Multiple Myeloma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Telemedicine Service Market https://www.delveinsight.com/report-store/telemedicine-service-market
Telemedicine Service Market By Service Type (Tele Consulting And Tele Monitoring), By Application (Telepathology, Telecardiology, Teleradiology, Teledermatology, Telepsychiatry, Other Services), By End-User (Healthcare Facilities And Homecare), by geography, is projected to grow at a significant CAGR forecast till 2028 owing to the sudden outbreak of covid-19 pandemic and shifting focus for reducing the burden of healthcare cost

Wearable Medical Devices Market https://www.delveinsight.com/report-store/wearable-medical-devices-market
Wearable Medical Devices Market By Device Type (Diagnostic And Monitoring Devices [Vital Sign Monitoring Devices, Sleep Monitoring Devices, Electrocardiographs Fetal And Obstetric Devices, Neuromonitoring Devices, And Others] And Therapeutic Devices [Pain Management Devices, Rehabilitation Devices, Respiratory Therapy Devices, And Others]), By Product Type (Wristband, Headband, Ear Wear, Watch, And Others), By Application (Sports And Fitness, Remote Patient Monitoring, And Home Healthcare), By Distribution Channel (Online And Offline), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to a rise in the geriatric population and increasing prevalence of chronic diseases across the globe.

Surgical Robotic System Market https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical Robotic Systems Market By Application (Urology, Gynecology, Neurosurgery, Orthopedics, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), And by geography is estimated to register appreciable CAGR forecast till 2028 owing to increase in surgical procedures and rising popularity of minimally invasive surgical interventions.

Cancer Diagnostics Market
https://www.delveinsight.com/report-store/cancer-diagnostic-market
Cancer Diagnostics Market By Type (Product Type [Reagent & Kits and Instruments], and Services), Technique (Molecular Diagnostics [Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH), Microarray, and Immunohistochemistry], Diagnostics Imaging [Ultrasound & Radiology, Mammography, MRI Scan, CT Scan, and Nuclear Medicine Scans], Endoscopy, and Biopsy [Standard Biopsy and Liquid Biopsy]), Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, and Others), End-User (Hospitals, Diagnostics Labs, and Others), and Geography, is expected to grow at a significant CAGR forecast till 2028 owing to the growing burden of cancer across the globe and rise in various product launches for efficient detection of cancer.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to lauch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.